Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of diagnosing alzheimer's disease and markers identified by set association

a technology of genetic markers and alzheimer's disease, applied in the field of detection of genetic markers and methods of diagnosing and screening for alzheimer's disease, can solve the problems of reducing life quality, overproduction of toxic a-1-42, etc., and achieve the effects of decreasing and reducing or preventing neuronal cell deterioration

Inactive Publication Date: 2009-10-15
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE +1
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The identification of GAB2 haplotypes enables accurate risk assessment and potential therapeutic strategies, potentially delaying disease progression and reducing healthcare costs by improving early detection and treatment of LOAD.

Problems solved by technology

Disorders of the brain are serious medical conditions causing disability and diminished quality of life.
Most of the pathogenic mutations in the APP and presenilin genes are associated with abnormal processing of APP, which leads to the overproduction of toxic Aβ-1-42.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of diagnosing alzheimer's disease and markers identified by set association
  • Methods of diagnosing alzheimer's disease and markers identified by set association
  • Methods of diagnosing alzheimer's disease and markers identified by set association

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design

[0092]The software program STRUCTURE (Pritchard et al. (2000) Genetics 155:945-59) was used to test for underlying genetic stratification, using 5000 randomly selected SNPs with at least 100 SNPs per chromosome. Initial analysis yielded empirical evidence of three populations (K=3). One, which contained fourteen samples and was far removed from the rest of the study population, was eliminated from further analyses. STRUCTURE was re-run with K=2, and each sample was assigned an admixture of the resulting populations. Comparison of the resulting case and control populations defined by these admixture vectors yielded a silhouette score of 0.06, indicating that while the samples in this study are the likely result of admixture of two populations, the distribution of those populations is equivalent in cases and controls (Pritchard et al. (2000) Genetics 155(2):945-59).

example 2

Introduction to High-Density Genome-Wide Association Study

[0093]The genome-wide association study was performed using 502,627 SNPs on DNA samples extracted from brain tissue or blood of donors who were at least 65 years of age at the time of their death. The donors included a postmortem cohort of 664 patients who satisfied clinical and neuropathological criteria for the diagnosis of AD and 422 persons that did not meet clinical or neuropathological criteria for AD as controls (broken up into a 70% “discovery cohort” and a 30% “replication cohort 1” design). Tissue and neuropathological diagnoses were supplied by investigators from twenty National Institute on Aging Alzheimer's Disease Centers (ADCs) in accordance with an agreement with these Centers, the National Institute on Aging, and the National Alzheimer's Coordinating Center (NACC). Additional post-mortem samples were received from Sun Health Research Institute and the Netherlands Brain Bank. An additional sample series includ...

example 3

High-Density Genome-Wide Association Study Specifics

[0096]Individualized genome-wide surveys were performed in a “neuropathological discovery cohort” of 749 expired brain donors, a “neuropathological replication cohort” of 307 expired brain donors, and an additional “clinical replication cohort” of 369 living subjects who were at least 65 years old at the time of their death or last clinical assessment and who were independently assessed for their APOE genotype. For the two neuropathological cohorts, brain tissue for DNA extraction, neuropathological diagnoses and data were supplied by investigators from twenty of the National Institute on Aging (NIA) sponsored Alzheimer's Disease Centers (ADCs) (in accordance with agreements with the NIA, the ADCs and the National Alzheimer's Coordinating Center) and from the Netherlands Brain Bank. 70% of the 1,056 expired LOAD cases and controls were randomly assigned to the hypothesis-generating neuropathological discovery cohort and the remaini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
nucleic acid hybridizationaaaaaaaaaa
pharmaceutical compositionaaaaaaaaaa
nucleic acid sequenceaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. Ser. No. 12 / 148,728, filed Apr. 21, 2008, which claims the benefit of U.S. Provisional Application Ser. No. 60 / 933,583, filed Jun. 6, 2007, and U.S. Provisional Application Ser. No. 60 / 925,638, filed Apr. 20, 2007, all of which are hereby incorporated by reference in their entireties.BACKGROUND[0002]1. Field[0003]The present disclosure relates to genetic markers, compositions for the detection of genetic markers and methods of diagnosing and screening for Alzheimer's disease (AD). Further encompassed are therapeutic methods and agents for decreasing the deterioration of cells associated with AD and methods of screening such agents.[0004]2. Related Art[0005]Disorders of the brain are serious medical conditions causing disability and diminished quality of life. Neurological damage is largely irreversible and thus early diagnosis and close monitoring are critical to the successful treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A01K67/027C12Q1/68G01N33/53C40B30/04C07H21/04
CPCA61K31/7088A61K31/711A61K31/713C12N15/113C12Q2600/172C12Q1/6883C12Q2600/106C12Q2600/156C12Q2600/158C12N2310/14A61P25/28
Inventor STEPHAN, DIETRICH A.REIMAN, ERIC M.WEBSTER, JENNIFERHEWARD, CHRISTOPHER B.HEWARD, PAMELAPAPASSOTIROPOULOS, ANDREAS
Owner TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com